摘要
Abstract
Objective To investigate the clinical efficacy of sintilimab combined with lenvatinib in the treatment of middle-staged and advanced primary hepatocellular carcinoma,and to analyze its effect on serum immunoglobulin levels.Methods A total of 103 patients with middle-staged and advanced primary hepatocellular carcinoma admitted to 3201 Hospital of Hanzhong between January 2021 and September 2023 were selected.They were randomly divided into the combination group(sintilimab combined with lenvatinib treatment,n=52)and control group(lenvatinib monotherapy,n=51).The therapeutic effects,changes in serum immunoglobulins(IgG,IgA,IgM),liver function(aspartate aminotransferase[AST],alanine aminotransferase[ALT],total bilirubin[TBiL])levels,and adverse events were compared between the two groups.Results After treatment,the objective remission rate(ORR)was significantly higher in the combination group than the control group(80.77%vs.56.85%,P<0.05).However,there was no significant difference in the disease-control rate(DCR)between groups(P>0.05).Serum IgG,IgA,and IgM were significantly elevated after the treatment in the combination group(P<0.05),which were significantly higher than the control group(P<0.05).Moreover,changes before and after treatment in serum immunoglobins,including ΔIgG,ΔIgA,and ΔIgM were significantly higher in the combination group than the control group(P<0.05).AST,ALT,and TBiL were significantly reduced after the treatment in the combination group(P<0.05),which were significantly lower than the control group(P<0.05).Moreover,changes before and after treatment in the liver function indicators,including ΔAST,ΔALT,andΔTBiL were significantly higher in the combination group than the control group(P<0.05).There was no significant difference in the incidence of adverse events between groups(P>0.05).Conclusion Sintilimab combined with lenvatinib has significant efficacy in the treatment of middle-staged and advanced primary hepatocellular carcinoma,which can improve the quality of survival and immune function,and reduce the occurrence of adverse events like hypoproteinemia.This combination is worthy of clinical promotion.关键词
信迪利单抗/仑伐替尼/原发性肝癌/疗效/免疫球蛋白Key words
Sintilimab/Lenvatinib/Primary hepatocellular carcinoma/Efficacy/Immunoglobulin分类
医药卫生
